Sagimet Biosciences (SGMT) news
Recent news
Sagimet Biosciences advances Aurora phase 3 Denifanstat trial
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced that its AURORA Phase 3 clinical trial of denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of moderate to severe acne, is on track to begin patient enrollment in the fourth quarter of 2026. The company has identified all…
AInvest Wire · 6d agoSagimet Biosciences Q2 EPS USD -0.26
Sagimet Biosciences Inc. (NASDAQ: SGMT) reported a net loss per share of -$0.26 for the second quarter of 2026, reflecting continued financial challenges as the company advances its pipeline of therapies targeting fibrotic and metabolic diseases. The company’s financial results for the three months…
AInvest Wire · Aug 11, 2026ImportantSagimet Biosciences rockets 100% on NASH Study results
Sagimet Biosciences rockets 100% on NASH Study results Sagimet Biosciences, a clinical-stage biopharmaceutical company, recently announced positive interim data from its Phase 2b clinical trial (FASCINATE-2) with denifanstat, a fatty acid synthase (FASN) inhibitor, in non-alcoholic steatohepatitis…
AInvest Wire · Jan 22, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.